Singh Harvinder
Known title: EVP & PRESIDENT, INTERNATIONALCIK: 0001949782
Associated companies
Transaction History
| IART | ▼ Sell | Tax Withholding | 861 | $8K | 3/11/2026 | View on chart |
| IART | ▲ Buy | Option Exercise | 18,922 | $0 | 3/11/2026 | View on chart |
| IART | ▼ Sell | Tax Withholding | 5,190 | $50K | 3/11/2026 | View on chart |
| IART | ▲ Buy | Option Exercise | 1,216 | $0 | 3/10/2026 | View on chart |
| IART | ▼ Sell | Tax Withholding | 601 | $6K | 3/10/2026 | View on chart |
| IART | ▲ Buy | Option Exercise | 11,965 | $0 | 10/12/2025 | View on chart |
| IART | ▼ Sell | Tax Withholding | 3,281 | $44K | 10/12/2025 | View on chart |
| IART | ▲ Buy | Option Exercise | 2,356 | $0 | 3/11/2025 | View on chart |
| IART | ▼ Sell | Tax Withholding | 647 | $15K | 3/11/2025 | View on chart |
| IART | ▲ Buy | Grant | 9,508 | $0 | 3/11/2025 | View on chart |
| IART | ▲ Buy | Option Exercise | 1,180 | $0 | 3/10/2025 | View on chart |
| IART | ▼ Sell | Tax Withholding | 324 | $7K | 3/10/2025 | View on chart |
| IART | ▲ Buy | Option Exercise | 1,179 | $0 | 3/10/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
IART May Be 48% Undervalued Based on Cash Flow Analysis
A recent Yahoo analysis suggests Integra LifeSciences shares could be trading about 48% below their intrinsic value when cash flow is considered. The stock sits near its 13‑touch support level of $9.10 and an RSI of 41.6, indicating neither overbought nor oversold conditions. The average analyst target is $19.56, well above the current price, highlighting a potential valuation gap. This analysis may prompt a closer look at the company’s cash flow performance relative to market expectations.
IART May Be 48% Undervalued Based on Cash Flow Analysis. A recent Yahoo analysis suggests Integra LifeSciences shares could be trading about 48% below their intrinsic value when cash flow is considered. The stock sits near its 13‑touch support level of $9.10 and an RSI of 41.6, indicating neither overbought nor oversold conditions. The average analyst target is $19.56, well above the current price, highlighting a potential valuation gap. This analysis may prompt a closer look at the company’s cash flow performance relative to market expectations.